Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis-Reference-Cited by-同舟云学术

Bedquiline Resistance Mutations: Correlations with Drug Exposures and Impact on the Proteome in M. tuberculosis

Published:2023-07-18 Issue:7 Volume:67 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Xu Jian¹^ORCID,Li Dongshuo¹,Shi Jinghua¹,Wang Bin¹,Ge Fei¹,Guo Zhenyong¹,Mu Xiaopan¹,Nuermberger Eric²³^ORCID,Lu Yu¹^ORCID

Affiliation:

1. Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Tuberculosis and Thoracic Tumor Research Institute, and Beijing Chest Hospital, Capital Medical University, Beijing, China

2. Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

3. Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA

Abstract

Bedaquiline (BDQ) is an effective drug for the treatment of drug-resistant tuberculosis. Mutations in atpE , which encodes the target of BDQ, are associated with large increases in MICs. Mutations in Rv0678 that derepress the transcription of the MmpL5-MmpS5 efflux transporter are associated with smaller increases in MICs. However, Rv0678 mutations are the most common mutations that are associated with BDQ resistance in clinical isolates, and they also confer cross-resistance to clofazimine (CFZ).

Funder

Natural Science Foundation of Beijing Municipality

MOST | National Natural Science Foundation of China

Tongzhou High-level talents Development Support Plan

Beijing Hospital Authority

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.01532-22

Reference48 articles.

1. World Health Organization. 2022. Global Tuberculosis Report 2022. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022.

2. Approval of Novel TB Drug Celebrated—With Restraint

3. World Health Organization. 2022. WHO operational handbook on tuberculosis Module 4: treatment Drug-resistant tuberculosis treatment.

4. Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant Tuberculosis

5. Treatment Outcome of a Shorter Regimen Containing Clofazimine for Multidrug-resistant Tuberculosis: A Randomized Control Trial in China

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Decoding drug resistance in Mycobacterium tuberculosis complex: genetic insights and future challenges;Expert Review of Anti-infective Therapy;2024-09-04

2. Emerging bedaquiline-resistant tuberculosis;The Lancet Microbe;2023-12